miRecule and Sanofi have partnered to pioneer innovative approaches in rare diseases and advance a novel RNA therapeutic for patients with the genetic disorder FSHD. miRecule’s DREAmiR™ discovery platform, combined with Sanofi’s Nanobody® technology, enables the identification of disease-causing genetic abnormalities and the development of targeted RNA therapies. Leveraging patient data, the collaboration aims to accelerate the creation of safe and effective drugs, offering new treatment options for rare diseases like Facioscapulohumeral Muscular Dystrophy, where traditional methods have fallen short.

Read more: Partner Spotlight: miRecule and Sanofi drive the emergence of RNA therapeutics